As per normal review, CME Clearing’s Risk Management staff approved the addition of the following products to the SPAN 2 framework’s in-scope product list into SPAN 2 framework’s crude pod and equity pod. For avoidance of doubt, products that are added to the In-Scope Products list will be margined under the SPAN 2 methodology, however they may receive margin offsets against products that are margined under the SPAN methodology through Cross Model Offset (“CMO”).

For the full text for this advisory, click the link below.